Daniel Bethmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6980225/publications.pdf

Version: 2024-02-01

933264 887953 19 365 10 17 citations g-index h-index papers 24 24 24 769 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Multiparametric immune profiling in HPV– oral squamous cell cancer. JCI Insight, 2017, 2, .	2.3	149
2	Immunoprofiling as a predictor of patient's response to cancer therapyâ€"promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
3	P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. Clinical and Translational Radiation Oncology, 2017, 5, 6-11.	0.9	21
4	Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2019, 20, 375.	1.8	20
5	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 7032.	1.8	20
6	Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. Oncolmmunology, 2018, 7, e1373233.	2.1	19
7	Consequences of postnatal vascular smooth muscle EGFR deletion on acute angiotensin II action. Clinical Science, 2016, 130, 19-33.	1.8	17
8	Substance-specific importance of EGFR for vascular smooth muscle cells motility in primary culture. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1519-1533.	1.9	16
9	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. Methods in Molecular Biology, 2019, 1913, 13-31.	0.4	12
10	Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 620.	1.7	11
11	Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. Methods in Enzymology, 2020, 635, 67-79.	0.4	8
12	Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. BMC Cancer, 2019, 19, 155.	1.1	7
13	Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. Breast Care, 2021, 16, 637-647.	0.8	7
14	Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. Scientific Reports, 2019, 9, 12594.	1.6	4
15	Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells. Oncolmmunology, 2022, 11, 2069214.	2.1	4
16	Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus â€negative oral squamous cell carcinomas with negative resection margins. Head and Neck, 2021, 43, 568-576.	0.9	3
17	Assessment of the tumor immune-environment in patients with head and neck cancer., 2015, 3,.		1
18	Prognostic impact of cytoplasmatic EGFR upregulation in patients with oral squamous cell carcinoma: A pilot study. Molecular and Clinical Oncology, 2020, 13, 88.	0.4	0

#	Article	IF	CITATIONS
19	Abstract P4-07-15: Tumor infiltrating lymphocytes as a prognostic factor. Cancer Research, 2022, 82, P4-07-15-P4-07-15.	0.4	O